SS 31, also written SS-31 and known as elamipretide, MTP-131 or Bendavia, is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2′,6′-dimethyltyrosine. It belongs to the Szeto-Schiller family of mitochondria-targeted peptides and is studied in vitro for its interaction with cardiolipin on the inner mitochondrial membrane. Researchers use it to examine mitochondrial bioenergetics, reactive oxygen species and membrane structure in isolated mitochondria and cultured cells. This article covers its structure, mechanism, published research, applications and the handling requirements that affect data quality.
What is SS 31?
SS-31 is a four-residue peptide amide with the formula C32H49N9O5 and a molecular weight of about 639.8 Da for the free base. The sequence is built around an alternating aromatic-cationic pattern. The N-terminal residue is D-arginine, which resists aminopeptidases. The second residue is the unnatural amino acid dimethyltyrosine, whose two methyl groups flank the phenol hydroxyl and affect both its antioxidant behaviour and its hydrophobicity. The third residue is lysine, and the C-terminus is phenylalanine amide. At physiological pH the peptide carries a net charge of about +3, which is central to its mechanism.
The Szeto-Schiller peptides were developed by Hazel Szeto at Weill Cornell Medical College in collaboration with Peter Schiller, and the family takes its “SS” prefix from their names. Early reports described cell-permeable peptide antioxidants that localise to the inner mitochondrial membrane. A 2004 paper in the Journal of Biological Chemistry by Zhao and colleagues reported that such peptides inhibited mitochondrial swelling and oxidative cell death in experimental systems, and later work focused on SS-31 as a lead compound. Researchers will meet several names for the same molecule, including SS-31, MTP-131, Bendavia and elamipretide. The prefix “SS” is also used for related peptides with different sequences, so supplier documentation should state the sequence and mass.
Several structural features matter for the laboratory. The D-residue and the amidated C-terminus confer proteolytic stability, so the peptide is more durable in serum-containing media than a typical L-peptide of similar size. The absence of methionine, cysteine and tryptophan removes the usual oxidation liabilities, although the phenolic ring of dimethyltyrosine can still be oxidised under harsh conditions. The three cationic groups make the peptide highly water-soluble.
Mechanism of action
The best-supported mechanism centres on cardiolipin, an anionic phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is required for the formation of cristae, the folded membrane structures where oxidative phosphorylation takes place, and it helps organise respiratory chain complexes. Birk and colleagues proposed that, because SS-31 carries a net charge of +3 at physiological pH, it might bind cardiolipin by electrostatic attraction. Using a polarity-sensitive fluorescent analogue, they reported selective interaction with cardiolipin over other anionic phospholipids, and they concluded that this interaction explains the peptide’s partitioning to the inner mitochondrial membrane.
The second reported mechanism concerns cytochrome c. In the presence of cardiolipin and hydrogen peroxide, cytochrome c can act as a peroxidase and oxidise cardiolipin, an event linked to mitochondrial damage in ischemia models. The authors reported that SS-31 inhibited this peroxidase activity, and they suggested that the peptide-cardiolipin complex protects the heme iron of cytochrome c. Work with SS-31 and cardiolipin in the context of cristae structure has also reported preservation of membrane architecture in injury models.
Earlier studies of the Szeto-Schiller peptides also attributed antioxidant behaviour to the dimethyltyrosine residue, which can scavenge certain reactive oxygen species, and described inhibition of mitochondrial permeability transition (MPT) in isolated mitochondria. Researchers should note that the relative importance of direct scavenging, cardiolipin binding and MPT effects is still debated, and that interpretation depends on the model, the concentration and the way mitochondrial function is measured. Experiments that include a non-targeted antioxidant or a structurally related inactive peptide as a control help separate these effects.
What the research shows
Four sets of published work frame the field.
The first is the characterisation of cell-permeable peptide antioxidants. Zhao and colleagues, in the 2004 Journal of Biological Chemistry paper noted above, reported that peptides of this class entered cells, concentrated at the inner mitochondrial membrane and inhibited mitochondrial swelling and oxidative cell death in experimental systems. The paper introduced the structural logic of alternating aromatic and cationic residues that underlies the family.
The second is a cell-culture study of oxidative stress. Zhao and co-workers reported in Biochemical Pharmacology in 2005 that a mitochondria-targeted peptide prevented mitochondrial depolarisation and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. The experiments used a defined oxidant challenge, which makes them a common template for in-vitro protection assays.
The third is a rat model of ischemia-reperfusion. Szeto and colleagues reported in the Journal of the American Society of Nephrology in 2011 that, in a rat model of renal ischemia-reperfusion, SS-31 treatment was associated with protected mitochondrial structure and respiration during early reperfusion, faster recovery of ATP, and reduced apoptosis and necrosis of tubular cells. The study characterised the compound in an animal injury model and is available on PubMed.
The fourth is the cardiolipin study. Birk and colleagues, in JASN in 2013, used a fluorescent analogue to show selective binding to cardiolipin, reported inhibition of cytochrome c peroxidase activity, and described protection of cristae membranes and prevention of mitochondrial swelling in rats subjected to renal ischemia. It is the key reference for the mechanism described above and is indexed on PubMed, with an open-access full text in PubMed Central.
Readers should note that these studies come from a closely connected group of investigators and that independent replication is valuable when interpreting any single result.
Research applications
Mitochondrial bioenergetics is the main area. Isolated mitochondria and permeabilised cells are exposed to the peptide, and oxygen consumption, membrane potential, ATP synthesis and calcium retention capacity are measured with respirometry and fluorescent probes. Comparisons between treated and untreated preparations, with and without an oxidant or calcium challenge, are the typical design.
Oxidative stress research is a second area. Cell lines are challenged with tert-butyl hydroperoxide, hydrogen peroxide or inhibitors of the respiratory chain, and the peptide is used to probe how mitochondrial targeting affects reactive oxygen species, lipid peroxidation and cell viability. Membrane biophysics is a third, in which SS 31 serves as a cationic probe of cardiolipin-containing liposomes and supported bilayers, studied by fluorescence, calorimetry and spectroscopy.
Structural and ultrastructural work forms a fourth area, with electron microscopy used to assess cristae morphology after injury in cell or tissue preparations. Finally, analytical chemists use the peptide as a model for a short, highly cationic sequence containing an unnatural amino acid, which poses useful questions about retention, ion pairing and stereochemical purity in HPLC method development.
Purity, storage and handling
Verification begins with reversed-phase HPLC, monitored at 214 nm for the peptide bond and at about 275 to 280 nm for the aromatic residues, with purity commonly specified at 98% or above. The peptide is small and highly polar, so ion-pairing conditions and gradient design affect resolution, and the method should be stated on the certificate. Mass spectrometry should confirm the monoisotopic mass near 639.4 Da, which appears as an [M+H]⁺ ion at about m/z 640.4. Because the sequence contains a D-amino acid, stereochemical purity matters: racemisation during synthesis would produce diastereomers that can co-elute, so chiral amino acid analysis can be worth requesting for quantitative work. Net peptide content is a separate figure, as the vial also contains counter-ions and water.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing SS 31 should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and anyone comparing the best peptides supplier uk options can use those same documentation checks for any vendor.
A batch-specific certificate matters because impurity profiles vary between syntheses. Deletion sequences, incompletely deprotected dimethyltyrosine and stereoisomers can appear in a given run, and only the method details, batch number and test date show that the stated purity applies to the vial in hand. The salt form, usually acetate or trifluoroacetate, should be stated because residual trifluoroacetate can interfere with mitochondrial and cell-viability assays.
Lyophilised peptide is generally stored at -20°C, sealed and desiccated, and brought to room temperature before opening to prevent condensation. Short exposure to ambient temperature in transit is usually tolerated by dry powder. After reconstitution the peptide is more vulnerable. The sequence avoids methionine, cysteine and tryptophan, which removes the most common oxidation routes, but hydrolysis, adsorption to plastic and slow oxidation of the phenolic residue can still occur. Reconstituted stock is normally kept at 2-8°C for short periods and divided into single-use aliquots to avoid repeated freeze-thaw cycles, with low-binding tubes preferred at low concentrations. Stability windows depend on buffer, pH and concentration, so they should be taken from supplier data and confirmed in-house for critical assays.
Light sensitivity is moderate. The aromatic residues can undergo photo-oxidation, so amber vials or dark storage are advisable for powder and solutions. Standard COSHH assessment and institutional waste procedures apply.
Frequently asked questions
What is the sequence and molecular weight of SS-31?
SS-31 is the tetrapeptide D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2′,6′-dimethyltyrosine and the C-terminus is amidated. The formula is C32H49N9O5 and the molecular weight is about 639.8 Da for the free peptide. The salt form, usually acetate or trifluoroacetate, changes the weight of the supplied powder.
What does SS-31 bind in mitochondria?
Published work reports that SS-31 binds cardiolipin, an anionic phospholipid concentrated on the inner mitochondrial membrane. The peptide carries a net charge of about +3 at physiological pH, which favours electrostatic interaction with cardiolipin, and fluorescence studies reported selective binding compared with other anionic phospholipids.
How should lyophilised SS-31 be stored?
Lyophilised SS-31 is generally stored at -20°C in a sealed, desiccated container protected from light, and warmed to room temperature before opening. Reconstituted solutions are usually kept at 2-8°C for short periods as single-use aliquots, with stability limits and buffer compatibility confirmed from batch documentation.
Is SS-31 the same as elamipretide?
Yes. SS-31 is the research name for the same tetrapeptide also called elamipretide, MTP-131 and Bendavia. Because the “SS” prefix is also used for related Szeto-Schiller peptides with different sequences, a certificate should state the full sequence and observed mass to avoid confusion.
SS 31 is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.